Details of the Drug

General Information of Drug (ID: DMD725X)

Drug Name

Minjuvi

Synonyms

Tafasitamab

Indication

Disease Entry	ICD 11	Status	REF
Lymphoma	2A80-2A86	Phase 2	[1]
------------------------------------------------------------------------------------

ATC Code

L01FX12: Minjuvi

L01FX: Other monoclonal antibodies and antibody drug conjugates

L01F: MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES

L01: ANTINEOPLASTIC AGENTS

L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Drug Type

Antibody

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Lymphoma

ICD Disease Classification

2A80-2A86

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
B-lymphocyte surface antigen B4 (CD19)	DTT	CD19	2.33E-24	-1.06	-1.33

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05626322) A PHASE 1b/2 STUDY OF PF-07901801, A CD47 BLOCKING AGENT, WITH TAFASITAMAB AND LENALIDOMIDE FOR PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION. U.S.National Institutes of Health.
2	Tafasitamab: First Approval. Drugs. 2020 Nov;80(16):1731-1737.